DaVita (NYSE:DVA) Announces Quarterly Earnings Results

DaVita (NYSE:DVA) announced its quarterly earnings results on Thursday. The company reported $3.82 earnings per share for the quarter, topping analysts’ consensus estimates of $3.57 by $0.25, FiscalAI reports. The company had revenue of $3.58 billion for the quarter, compared to analysts’ expectations of $3.52 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%.

DaVita Stock Up 4.9%

NYSE DVA traded up $9.00 during trading hours on Thursday, reaching $192.93. 2,044,062 shares of the company were exchanged, compared to its average volume of 892,619. DaVita has a 1 year low of $101.00 and a 1 year high of $247.49. The business’s 50 day simple moving average is $180.81 and its 200-day simple moving average is $175.70. The stock has a market capitalization of $12.31 billion, a P/E ratio of 15.79, a P/E/G ratio of 0.48 and a beta of 0.80.

Analyst Ratings Changes

A number of equities analysts have weighed in on DVA shares. TD Cowen reissued a “buy” rating on shares of DaVita in a research report on Wednesday, October 21st. UBS Group raised their price target on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Truist Financial reduced their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th. Barclays upped their target price on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 9th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, DaVita currently has a consensus rating of “Moderate Buy” and an average price target of $233.43.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.